Paediatr Anaesth:儿童实际禁食时间和吸入性肺炎发生率的关系

2020-03-28 “罂粟花”微信号 “罂粟花”微信号

麻醉前长时间禁食在小儿手术中很常见。缩短禁食时间可以改善麻醉诱导过程中的代谢和血流动力学状况,改善父母和孩子的围术期体验,简化围术期管理。德国的一些手术中心降低了禁食要求,但国家指南仍未改变。

背景与目的

麻醉前长时间禁食在小儿手术中很常见。缩短禁食时间可以改善麻醉诱导过程中的代谢和血流动力学状况,改善父母和孩子的围术期体验,简化围术期管理。德国的一些手术中心降低了禁食要求,但国家指南仍未改变。因此,这项前瞻性的多中心观察性研究是由德国麻醉学和重症监护医学学会儿童麻醉科学工作组发起的,目的是在修订国家禁食指南之前评估实际禁食时间和吸入性肺炎发病率的相关性。

方 法

在伦理委员会批准后,至少有3000名儿童计划参与这项分析。使用标准化的病例报告记录患者的人口统计数据、实际禁食时间、麻醉和外科手术程序以及出现的反流或吸入性肺炎发生率。结果以中位数或发生率(百分比)表示。

结 果

2018年10月至2019年5月,10个儿童中心共纳入3324名儿童。大餐的实际禁食时间为14[12.2-15.6](0.5-24)小时,简餐9[5.6-13.3](0.25-28.3)小时,配方奶5.8[4.5-7.4](0.9-24)小时,母乳4.8[4.2-6.3](1.3-25.3)小时,清液2.7[1.5-6](0.03-22.8)小时。据报道,长期禁食(偏离指南>2小时)的情况有88.3%发生在大餐中,54.7%发生在简餐中,44.4%发生在配方奶中,25.8%发生在母乳中,34.2%发生在透明液体中。报告11例(0.33%)返流,4例(0.12%)疑似误吸,2例(0.06%)确诊吸入性肺炎;手术结束后均可拔管,恢复正常。

结 论

本研究表明,长时间禁食在德国儿科麻醉中仍较为常见,术后发生呼吸窘迫的肺误吸较为少见,急需对现行的局部禁食方案和国家禁食指南进行改进。

原始出处:

Beck CE, Rudolp D, Becke-Jakob K. Real fasting times and incidence of pulmonary aspiration in children: Results of a German prospective multicenter observational study. Paediatr Anaesth. 2019; 19:48

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051542, encodeId=9609205154285, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Oct 04 03:41:24 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639408, encodeId=866316394089a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 27 00:41:24 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928413, encodeId=6760192841376, content=<a href='/topic/show?id=f05a3938868' target=_blank style='color:#2F92EE;'>#吸入性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39388, encryptionId=f05a3938868, topicName=吸入性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Jul 15 02:41:24 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633570, encodeId=784a16335e025, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 21 11:41:24 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826591, encodeId=5e02182659156, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Aug 31 00:41:24 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489849, encodeId=a1f8148984981, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Mon Mar 30 05:41:24 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
    2020-10-04 xiangyuzhou971
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051542, encodeId=9609205154285, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Oct 04 03:41:24 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639408, encodeId=866316394089a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 27 00:41:24 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928413, encodeId=6760192841376, content=<a href='/topic/show?id=f05a3938868' target=_blank style='color:#2F92EE;'>#吸入性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39388, encryptionId=f05a3938868, topicName=吸入性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Jul 15 02:41:24 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633570, encodeId=784a16335e025, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 21 11:41:24 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826591, encodeId=5e02182659156, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Aug 31 00:41:24 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489849, encodeId=a1f8148984981, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Mon Mar 30 05:41:24 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051542, encodeId=9609205154285, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Oct 04 03:41:24 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639408, encodeId=866316394089a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 27 00:41:24 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928413, encodeId=6760192841376, content=<a href='/topic/show?id=f05a3938868' target=_blank style='color:#2F92EE;'>#吸入性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39388, encryptionId=f05a3938868, topicName=吸入性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Jul 15 02:41:24 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633570, encodeId=784a16335e025, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 21 11:41:24 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826591, encodeId=5e02182659156, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Aug 31 00:41:24 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489849, encodeId=a1f8148984981, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Mon Mar 30 05:41:24 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051542, encodeId=9609205154285, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Oct 04 03:41:24 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639408, encodeId=866316394089a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 27 00:41:24 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928413, encodeId=6760192841376, content=<a href='/topic/show?id=f05a3938868' target=_blank style='color:#2F92EE;'>#吸入性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39388, encryptionId=f05a3938868, topicName=吸入性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Jul 15 02:41:24 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633570, encodeId=784a16335e025, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 21 11:41:24 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826591, encodeId=5e02182659156, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Aug 31 00:41:24 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489849, encodeId=a1f8148984981, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Mon Mar 30 05:41:24 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
    2020-04-21 AspirantSuo
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051542, encodeId=9609205154285, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Oct 04 03:41:24 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639408, encodeId=866316394089a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 27 00:41:24 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928413, encodeId=6760192841376, content=<a href='/topic/show?id=f05a3938868' target=_blank style='color:#2F92EE;'>#吸入性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39388, encryptionId=f05a3938868, topicName=吸入性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Jul 15 02:41:24 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633570, encodeId=784a16335e025, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 21 11:41:24 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826591, encodeId=5e02182659156, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Aug 31 00:41:24 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489849, encodeId=a1f8148984981, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Mon Mar 30 05:41:24 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2051542, encodeId=9609205154285, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Oct 04 03:41:24 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639408, encodeId=866316394089a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 27 00:41:24 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928413, encodeId=6760192841376, content=<a href='/topic/show?id=f05a3938868' target=_blank style='color:#2F92EE;'>#吸入性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39388, encryptionId=f05a3938868, topicName=吸入性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Jul 15 02:41:24 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633570, encodeId=784a16335e025, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 21 11:41:24 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826591, encodeId=5e02182659156, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Aug 31 00:41:24 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489849, encodeId=a1f8148984981, content=<a href='/topic/show?id=bcd5204ea9' target=_blank style='color:#2F92EE;'>#AED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2047, encryptionId=bcd5204ea9, topicName=AED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0108610571, createdName=makuansheng, createdTime=Mon Mar 30 05:41:24 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
    2020-03-30 makuansheng

相关资讯

PNAS:禁食通过β-羟基丁酸减少炎症,缓解肝损伤

肝脏缺血和再灌注损伤(IRI)是肝脏手术中的主要挑战。饮食限制通过增加抗压力来减少肝损伤,然而,至今为止,其潜在的分子机制仍不清楚。

CELL METAB:临床试验显示,隔日禁食是一种安全的热量限制替代方案

已知热量限制和间歇性禁食可以延长模式生物体的生命和健康,但是至今为止,关于它们对人类的影响的研究还较少。

2019 ASIPP指南:接受介入性疼痛治疗患者的镇静和禁食状态

2019年5月,美国介入疼痛医师协会(ASIPP)发布了接受介入性疼痛治疗患者的镇静和禁食状态指南。许多接受介入性疼痛治疗的患者每日服用的药物包括止痛药,肌肉松弛剂以及其他在围术期具有明显协同作用的药物。本文主要内容涉及接受介入性疼痛治疗患者的镇静和禁食情况。

Obesity:想减肥?试试定时进餐策略

众所周知,白天早点儿吃,晚上早点儿睡,符合新陈代谢的昼夜节律,有助于我们减肥或保持体重。然而,研究人员尚不清楚这些益处是否通过增加能量消耗或减少食物摄入来调节。

Nutri Metab Cardiovas:降低心衰风险、延长心血管疾病患者寿命,间歇性禁食益处多多!

导语:间歇性禁食最初因“网红减肥法”而被大家所熟知,近些年更因为其可改善类风湿性关节炎、多发性硬化症以及糖尿病患者的病情而备受热议。

Obesity:改善代谢哪家强,隔日禁食还是节食?

根据发表在Obesity杂志上的研究结果,在超重或肥胖且有胰岛素抵抗的成人中,隔日禁食降低空腹胰岛素和胰岛素抵抗水平的程度大于限制热量摄入。